Orchard Therapeutics PLC
Carlotta Peticone has a strong background in bioengineering and regenerative medicine. With experience in various roles at Orchard Therapeutics, Autolus Ltd., and academic institutions like University College London and The University of Queensland, Carlotta has worked on projects related to cell process development, gene therapy, and bone regeneration. Carlotta holds a Ph.D. in Biochemical Engineering from UCL and has expertise in areas such as scale-up, differentiation, and vascularization.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.